Periprosthetic osteolysis remains a major cause of implant failure, driven by inflammatory responses to titanium (Ti) wear particles and ions. Inflammatory bowel disease (IBD), a systemic chronic inflammatory condition, exacerbates bone loss, yet its synergistic effects with Ti ions on periprosthetic osteolysis remain unexplored. Here, we investigated how IBD and Ti ions impair bone-implant integration by disrupting osteogenesis via the PI3K/AKT pathway. A rat model of IBD with localized Ti ion exposure was established, alongside in vitro studies using bone marrow mesenchymal stem cells (BMSCs). Micro-CT and histomorphometry revealed severe trabecular bone loss and reduced bone-implant contact (BIC) in the Ti + DSS group, accompanied by increased osteoclast activity and suppressed osteogenic markers (Runx2/Sp7/OPN). Luminex assays showed elevated pro-inflammatory cytokines (such as CXCL1, CCL5 and CCL20) in bone marrow microenvironment, further amplified by Ti ions. RNA sequencing of BMSCs identified downregulation of osteogenic differentiation genes and inhibition of the PI3K/AKT pathway. In vitro, AKT activation rescued osteogenic differentiation and mineralization in BMSCs exposed to Ti + DSS-conditioned inflammatory factors. These findings demonstrate IBD and Ti ions synergistically exacerbate periprosthetic osteolysis by enhancing osteoclastogenesis and suppressing BMSC osteogenesis via PI3K/AKT signaling. Targeting this pathway may offer therapeutic strategies to improve implant longevity in IBD patients.
Tooth implant treatment is frequently accompanied by postoperative pain and swelling. While dexamethasone is known to mitigate these symptoms, the optimal administration method remains unclear. This study compared the effects of different administration methods of dexamethasone on alleviating pain and swelling after flap implantation surgery. Patients with dentition defects requiring implant treatment were grouped according to whether dexamethasone was administered via submucosal injection during the surgery or orally after the surgery. Pain and swelling levels were measured and recorded within 72 h post-operation, along with potential influencing factors including gender, age, number of implants, duration of surgery, oral hygiene status, preoperative anxiety level, and pain sensitivity score using Pain Sensitivity Questionnaire (PSQ). The differences in pain and swelling between the two groups at different time points were compared, and Pearson correlation and multiple linear regression analyses were conducted on the potential influencing factors. While pain and swelling scores in the submucosal injection group were consistently lower than in the oral group at all time points, these intergroup differences did not reach statistical significance (P > 0.05). However, significant time effects were observed within each group (P < 0.05), with swelling reduction occurring earlier in the submucosal injection group (24 h vs 48 h). Correlation and regression analyses showed that higher scores in PSQ-total and preoperative anxiety level, as well as a greater number of implants, were associated with higher pain levels, while postoperative swelling was significantly greater in females than in males. Intraoperative submucosal dexamethasone was associated with earlier swelling reduction compared to oral administration, though both methods showed comparable pain control. These findings suggest a potential clinical advantage for the intraoperative route that warrants further investigation. This study was registered on Chinese Clinical Trial Registry, and the trial registration number is ChiCTR2500098816. Registered March 13, 2025- Retrospectively registered, https://www.chictr.org.cn/bin/project/edit?pid=257854 .